卡格列净使用对一年随访期体重和血压的影响：一项系统评价和荟萃分析。 - Suppr | 超能文献

相似文献

1

Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: A systematic review and meta-analysis.卡格列净使用对一年随访期体重和血压的影响：一项系统评价和荟萃分析。

Eur J Prev Cardiol. 2019 Oct;26(15):1680-1682. doi: 10.1177/2047487319829940. Epub 2019 Feb 12.

2

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.卡格列净对2型糖尿病患者射血分数保留和降低的心衰结局的影响。

Circulation. 2019 May 28;139(22):2591-2593. doi: 10.1161/CIRCULATIONAHA.119.040057. Epub 2019 Mar 17.

3

The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.CANVAS 项目：卡格列净对降低 2 型糖尿病患者心血管风险的影响。

Cardiovasc Diabetol. 2019 May 28;18(1):64. doi: 10.1186/s12933-019-0869-2.

4

Canagliflozin for Japanese patients with chronic heart failure and type II diabetes.坎格列净用于日本慢性心力衰竭合并 2 型糖尿病患者。

Cardiovasc Diabetol. 2019 Jun 5;18(1):76. doi: 10.1186/s12933-019-0877-2.

5

SGLT2 inhibitors and lower limb complications: an updated meta-analysis.SGLT2 抑制剂与下肢并发症：一项更新的荟萃分析。

Cardiovasc Diabetol. 2021 Apr 28;20(1):91. doi: 10.1186/s12933-021-01276-9.

6

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.根据基线肾功能评估坎格列净的心血管和肾脏结局。

Circulation. 2018 Oct 9;138(15):1537-1550. doi: 10.1161/CIRCULATIONAHA.118.035901.

7

Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes.卡格列净在降低2型糖尿病患者心血管风险方面的临床潜力。

Vasc Health Risk Manag. 2018 Dec 7;14:419-428. doi: 10.2147/VHRM.S168472. eCollection 2018.

8

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).卡格列净用于心血管事件的一级和二级预防：来自 CANVAS 项目（卡格列净心血管评估研究）的结果。

Circulation. 2018 Jan 23;137(4):323-334. doi: 10.1161/CIRCULATIONAHA.117.032038. Epub 2017 Nov 13.

9

[Not Available].[无可用内容]

CMAJ. 2021 Nov 15;193(45):E1746-E1749. doi: 10.1503/cmaj.202627-f.

10

Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.钠-葡萄糖共转运蛋白 2 抑制剂卡格列净治疗 2 型糖尿病患者血清酮体增加的个体内和个体间变异性。

Diabetes Obes Metab. 2018 May;20(5):1321-1326. doi: 10.1111/dom.13224. Epub 2018 Feb 14.

引用本文的文献

1

A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications.关于抗糖尿病药物相关体重减轻的综合综述

Life (Basel). 2023 Apr 14;13(4):1012. doi: 10.3390/life13041012.

2

Diabetes: how to manage overweight and obesity in type 2 diabetes mellitus.糖尿病：如何管理2型糖尿病患者的超重和肥胖问题。

Drugs Context. 2022 Jun 14;11. doi: 10.7573/dic.2021-11-7. eCollection 2022.

3

Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis.钠-葡萄糖共转运蛋白 2 抑制剂改善冠状动脉疾病患者的心脏肾脏结局：一项荟萃分析。